1. Home
  2. SKYE vs ORN Comparison

SKYE vs ORN Comparison

Compare SKYE & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • ORN
  • Stock Information
  • Founded
  • SKYE 2012
  • ORN 1994
  • Country
  • SKYE United States
  • ORN United States
  • Employees
  • SKYE N/A
  • ORN N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • ORN Military/Government/Technical
  • Sector
  • SKYE Health Care
  • ORN Industrials
  • Exchange
  • SKYE Nasdaq
  • ORN Nasdaq
  • Market Cap
  • SKYE 176.8M
  • ORN 282.2M
  • IPO Year
  • SKYE N/A
  • ORN 2007
  • Fundamental
  • Price
  • SKYE $5.89
  • ORN $11.39
  • Analyst Decision
  • SKYE Strong Buy
  • ORN Strong Buy
  • Analyst Count
  • SKYE 4
  • ORN 2
  • Target Price
  • SKYE $19.25
  • ORN $13.25
  • AVG Volume (30 Days)
  • SKYE 386.3K
  • ORN 762.5K
  • Earning Date
  • SKYE 01-01-0001
  • ORN 07-24-2024
  • Dividend Yield
  • SKYE N/A
  • ORN N/A
  • EPS Growth
  • SKYE N/A
  • ORN N/A
  • EPS
  • SKYE N/A
  • ORN N/A
  • Revenue
  • SKYE N/A
  • ORN $713,276,000.00
  • Revenue This Year
  • SKYE N/A
  • ORN $21.94
  • Revenue Next Year
  • SKYE N/A
  • ORN $11.35
  • P/E Ratio
  • SKYE N/A
  • ORN N/A
  • Revenue Growth
  • SKYE N/A
  • ORN N/A
  • 52 Week Low
  • SKYE $1.44
  • ORN $2.91
  • 52 Week High
  • SKYE $19.41
  • ORN $11.61
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 34.36
  • ORN 68.68
  • Support Level
  • SKYE $5.95
  • ORN $8.18
  • Resistance Level
  • SKYE $6.83
  • ORN $8.69
  • Average True Range (ATR)
  • SKYE 0.82
  • ORN 0.57
  • MACD
  • SKYE 0.09
  • ORN 0.30
  • Stochastic Oscillator
  • SKYE 21.26
  • ORN 93.58

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About ORN Orion Group Holdings Inc. Common

Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas.

Share on Social Networks: